EE318 Evaluating the Cost Effectiveness of the Towards Home-Based Albuminuria Screening (THOMAS) Study for Early Detection and Treatment of Chronic Kidney Disease

Xavier Pouwels(University of Twente), Hendrik Koffijberg(University Medical Center Utrecht), Cornelis Boersma(University Medical Center Groningen), LM Kieneker(University Medical Center Groningen), Dominique van Mil(University Medical Center Groningen), RT van Gansevoort(University Medical Center Groningen)
Value in Health
December 1, 2022
10.1016/j.jval.2022.09.564
Cited by 0

Related Papers

A new framework to enhance the interpretation of external validation studies of clinical prediction models
|Journal of Clinical Epidemiology|2014|555
Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study
|The Lancet|2023|72
Screening for chronic kidney disease: change of perspective and novel developments
|Current Opinion in Nephrology & Hypertension|2024|35
Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease
|EClinicalMedicine|2024|34
Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps
|Clinical Kidney Journal|2023|19